ResMed (RMD) Reports In-Line Q1 EPS
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $205.84 --0%
Revenue Growth %: +13.1%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: +13.1%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q1 EPS of $1.51, in-line with the analyst estimate of $1.51. Revenue for the quarter came in at $950.3 million versus the consensus estimate of $947.96 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman lowers Mattel rating to Sell on macro and execution risks; shares dip
- Steel Partners offers $16.75 per share to acquire InMode
- Donerail urges Beazer Homes board to engage with DFH's $32 offer
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
